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ABSTRACT	
Master Thesis, Programme in Medicine 
Title: Long-term outcome 12-15 years after aneurysmal subarachnoid haemorrhage: a 
prospective cohort study  
Author, Year: Erika Svanborg, 2015 
Institute, City, Country: Department of Anaesthesiology and Intensive Care, Sahlgrenska 
Academy, University of Gothenburg, Sweden.   
 
Background: Aneurysmal subarachnoid haemorrhage (aSAH) is a severe disease with poor 
outcome. Few studies on long-term outcome exist. Therefore we initiated this outcome study, 
12-15 years post-aSAH on a previously validated patient-cohort at admission and at 1-year. 
 
Aim: To investigate long-term outcomes using the Glasgow Outcome Scale (GOS). We 
hypothesized to find 1) functional improvement > 1-year post-ictus, 2) increased long-term 
mortality in aSAH patients vs. matched controls, and 3) predictors of long-term favourable 
outcome (GOS 4-5).  
 
Methods: We prospectively investigated data of patients admitted to the Sahlgrenska 
University Hospital (SU), 2000-2003. GOS, 12-15 years post-aSAH was validated by 
structured-telephone interviews and compared to previous GOS at 1-year follow-up.  
Mortality was analysed by Kaplan-Meier survival curves vs. age-, gender-, calendar year - 
and area-matched controls. Uni- and multivariable logistic regression analyses were applied to 
determine independent predictors of long-term favourable outcome.  
 
Results: 158 aSAH-patients of 212 study candidates were included, with women 72.2% and 
mean age 55-years (SD 10.7). In a complete follow-up at 12-15 years post-aSAH, the 103 
survivors (65.2%) were categorized: good recovery (39.9%, n=63), moderate disability 
(15.2%, n=24) and severe disability (10.1%, n=16). 55 had died at median 3.95 years (0.01-
13.7). In the patient cohort 23.6% (n=30) improved GOS. There was a significant 
deterioration when dichotomized outcomes in unfavourable and favourable (p=0.0002). Age 
(p>0.022) and Hunt and Hess (p<0.0008) correlated to worse GOS at 12-15 years, but not 
gender, (p=0.69). aSAH-patients had 3.5 times increased mortality 12-15 years post-ictus vs. 
matched controls (p<0.0001). Patients with favourable outcome at 1-year (67.3%, n=101) had 
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the same survival probability as controls (p=0.27). The highest prognostic indicators of long-
term favourable outcome were high GOS and low age at 1-year (AUCROC, 0.79).  
 
Conclusions: Individual functional improvement occurred >1-year post-ictus. Patients with 
favourable outcome at 1-year had the same long-term life expectancy as the general 
population. High age and severe clinical status are risk factors for poor outcome. The best 
indicators of long-term favourable prognosis were GOS and age at 1-year follow-up.  
 
Keywords: aneurysmal subarachnoid haemorrhage, functional outcome, Glasgow Outcome 
Scale, mortality, predictors 					
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ABBREVIATIONS	
ADL – Activity of Daily Living  
aSAH – aneurysmal Subarachnoid Haemorrhage  
AUC – Area Under the Curve 
BI – Barthel Index  
CSF – Cerebrovascular fluid  
CVS – Cerebral Vasospasm  
CT – Computed Tomography 
CTA – Computed Tomography Angiography 
DSA – Digital Subtractions Angiography  
GCS – Glasgow Coma Scale  
GOS – Glasgow Outcome Scale 
GOSE – Glasgow Outcome Scale Extended 
Hunt-Hess  – Hunt and Hess scale 
ISAT – International Subarachnoid Aneurysm Trial 
LP – Lumbar Puncture 
MRA – Magnetic Resonance imaging Angiography  
mRS – modified Rankin Scale 
NICU – Neuro-Intensive Care Unit  
NIHSS – National Institute of Health Stroke Scale 
OD – Odds ratio 
RLS 85 – Reaction Level Scale 
ROC – Receiver operator characteristic curve 
SAH – Subarachnoid Haemorrhage  
S-GOS 04 - Swedish version of Glasgow Outcome Scale  
SMR - Standard Mortality Ratio 
SU - Sahlgrenska University Hospital    
WFNS – World Federation of Neurosurgical Surgeons Scale  
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INTRODUCTION	
The brain´s complexity distinguishes it from other organs. Similarly, brain insults have 
special characteristics, as it often contributes to both physical and psychological disabilities 
(1-3). Further, previous knowledge imply that recovery after brain insults, like one of the 
stroke entities aneurysmal Subarachnoid Haemorrhage (aSAH) have potential to improve over 
prolonged time (1, 4). Studies assessing outcome beyond 1-year are lacking and consequently 
late recovery following aSAH is poorly investigated (5-10). Thus long-term mortality and 
morbidity regarding aSAH-patients need to be further investigated (10, 11). Therefore we 
initiated this outcome study, 12-15 years after onset of the aSAH.  
 
The present extended long-term study is established on a prospectively study cohort enrolled 
at Sahlgrenska University Hospital (SU), between October 2000 and December 2003 (12, 13). 
These aSAH-patients were consecutive included and thoroughly investigated both at 
admission and 1-year post-ictus. The 1-year follow-up included extensive neurological 
examination as well as outcome assessment by Glasgow Outcome Scale, Extended (GOSE), 
all performed by the same neurologist. It was particularly interesting to investigate the same 
study cohort 12-15 years after the insult, as this study population from West Sweden, was 
priory extensive evaluated and had received standardized treatment at SU.  
 
Our hypotheses were:   
1. Is it possible to detect functional improvement > 1-year post-aSAH.  
2. Patients with aSAH have increased long-term mortality compared matched controls.   
3. It is possible to detect predictors like age, gender and admission status at onset and/ or 
at 1-year post-aSAH and correlate them to long-term functional outcome.  
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BACKGROUND	
Subarachnoid Haemorrhage (SAH) is a haemorrhage from a blood vessel within the 
subarachnoid space (13, 14). The major ethology is a ruptured, saccular intracranial 
aneurysm(s) (85%) at the base of the brain, from the circulus arteriosus Willisii and its 
branches (14, 15). SAH can also be induced by perimesencephalic haemorrhage (10%), a 
venous benign bleeding and other rare causes (5%) e.g. arterial dissection, cerebral 
arteriovenous malformations, septic aneurysm, cocaine abuse and trauma (16). Further, 
intracranial aneurysm develops with age and the rupture risk increase with size, particularly in 
the posterior circulation (17). However, a majority of all ruptured aneurysms are small 
(<10mm) and located in the anterior circulation (16, 18). The fact that multiple aneurysms 
may be detected in connection with the diagnosis of the aSAH (18), that de novo intracranial 
aneurysm may develop after the first insult (19), and that the risk of a new aSAH in survivors 
is 15 times higher compared with the general population (20), makes this devastating 
haemorrhagic stroke horrifying. Fortunately, the majority of all intracranial aneurysm, who 
appear in 2-5 % of adults in the general population, will never rupture (20, 21). 
 
 SAH accounts for a minority of all strokes (5%) (16, 21, 22). Although the average age at 
onset is lower (mean 55 years), the morbidity and mortality is substantial compared to 
intracerebral haemorrhage and ischemic stroke (4, 18, 23, 24). Whereas 12% of all aSAH-
patients die immediately (25-27), more than 30% die within 1-month (24), 25-50% die within 
6-months (28) and of survivors 30% remain dependent (14). Despite the bleak outcome, the 
current overall case-fatality rate of 30% (10-60%) has decreased with 17% since 1970s (24). 
In accordance the case-fatality rate in Sweden has reduced over the last three decades (27). 
However, the relatively young age at onset of the aSAH and the poor outcome, contribute to 
considerable loss of productive life years, in similar extent as that from ischemic stroke (23, 
29).  	
The global incidence of aSAH is 9 per 100 000 person-year (18), though it varies in the world 
and within countries (18, 21). The incidence is much higher in Finland and Japan, 
approximately 20 per 100 000 person-year (21), and in Sweden it is higher in north (15.2 per 
100 000 person-year) than in south (11.4 per 100 000 person-year). Hence the overall 
incidence in Sweden is 12.4 per 100 000 person-year (27). Further, the incidence of aSAH 
increase with female gender (1.3-1.6 times), age, non-white ethnicity, autosomal dominant 
polycystic kidney disease (ADPKD) and for a positive family history of aSAH (20, 21, 23, 
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27, 30, 31). Despite, that first-degree relatives of patients with aSAH have 3 to 7 times higher 
risk to suffer the same insult than the general population (32), the familial-aSAH accounts for 
a minority (10%) of all aSAH i.e. the majority are spontaneous-aSAH (33).  
 
Further, independent modifiable risk factors for aSAH are current smoking (RR 2.2 95% CI 
1.3-3.6), hypertension (RR 2.5 95% CI 2.0-3.1) and excessive alcohol intake (>150g per 
week) (RR 2.1 95% CI 1.5-2.8) (30, 34). Interestingly, it is suggested that hormone 
replacement therapy and hypercholesterolemia reduced the risk for aSAH (30). Thus, 
prevention of the devastating haemorrhagic stroke, with a heritable component is possible and 
for sure all aSAH-patients should stop smoking.  
 
The cardinal symptom of a ruptured intracranial aneurysm, is sudden (within seconds) severe 
headache “thunderclap-headache”, often (2/3) associated with other symptoms e.g. depressed 
consciousness, acute confusional state, seizures, vomiting, oculomotor nerve palsy and neck 
stiffness (3-12 hours post-ictus) (35). The first investigation if SAH is clinically suspected is a 
non-contrast computed tomography (CT). CT scan is the golden standard for SAH diagnostic 
(18), and modern 3rd generation CT scan has a sensitivity of 97% to 100% to detect SAH, 
when performed by an experienced radiologist within 6 hour after onset of the headache (36). 
The most characteristic sign of SAH is the “crab of death” i.e. subarachnoid blood in the 
subarachnoid space/ basal cisterns (18). However, if the patient presents “thunderclap 
headache” and a negative CT scan a lumbar puncture (LP) is obtained, after minimum 6 hours 
post-ictus (16). Centrifugation followed by spectrophotometry of the cerebrospinal fluid 
(CSF) enables us to distinguish between SAH-blood (i.e. breakdown of erythrocytes to 
bilirubin, wavelength 456 nm) and a traumatic puncture (oxyhemoglobin, wavelength 415nm) 
(13, 37). Further, the aSAH diagnosis is followed by a CT angiography (CTA) involving 
contrast injection, easily obtained after the CT scan and enables 3D reconstruction of the 
intracranial vessels malformations (13, 14). Magnetic resonance imaging angiography (MRA) 
is an alternative to the CTA, but unsuitable in agitated patients and patients who need 
extensive monitoring (18), hence MRA is no emergency investigation for aSAH. Finally, 
digital subtractions angiography (DSA) is performed, an invasive investigation involving 
puncture of a major artery (often femoral artery) and contrast injection, facilitates detailed 3D 
mapping of the ruptured aneurysm(s) (13, 18).  
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Treatment routines of intracranial aneurysms and SAH at SU (neurosurgical department) 
follow a well-established standardized protocol, in agreement with The European Stroke 
Organisations guidelines (18). At admittance extended monitoring and general management 
are obtained, follow by the primary objective of the aSAH treatment, i.e. to occlude the 
ruptured aneurysm and prevent from re-bleeding (13). Re-bleeding is the most frightful early 
complication affecting 15 % of all patients within the first 24 hours (38, 39). Thus, 
Tranexamic acid (Cyklapron® i.v. 1g three times daily), a fibrinolysis inhibitor is 
administrated immediately after the diagnosis of SAH, until the ruptured intracranial 
aneurysm(s) is secured (13, 38). The occlusion is performed either by endovascular coiling or 
neurosurgical clipping, depending on factors such as patient age, comorbidity, aneurysm; size, 
localization and configuration, and is a decision taken in agreement between the neurosurgeon 
and the intervention neuroradiologist (13, 18). The major difference between the interventions 
is that clipping involves open craniotomy and brain manipulation (40). After occlusion of the 
ruptured aneurysm(s) Nimodipine, a calcium antagonist is administrated (infusion or orally 
for 10 days) to prevent delayed cerebral ischemia (cerebral vasospasm, CVS) and improve 
outcome. Further, acute hydrocephalus is treated (when needed) with an intra-ventricular 
catheter for CSF drainage. Intracranial haemorrhage is removed at initial surgical or if 
extensive. Conservative treatment i.e. no active aneurysmal intervention (the aneurysm is left 
untreated) is applied in 2-4% cases (13). Among those approximately one third die within 6 
months (18). Finally, patients are cared and monitored in specialised Neuro-Intensive Care 
Units (NICU), followed by rehabilitation at neuro-rehabilitation centres (13, 41, 42).  
 
Our aim was not to compare aneurysmal treatment interventions i.e. endovascular coiling vs. 
neurosurgical clipping, although a current published study (2015) need to be commented. 
Molyenux et al. (43) performed a large, randomized, multicentre, 18-year follow-up study 
(International Subarachnoid Aneurysmal Trial, ISAT) comparing the interventions among 
patients equally acceptable for coiling vs. clipping. They reported significantly reduced 
mortality and independency at 10-years post-aSAH for patients allocated to coiling. Thus, the 
beneficial outcome favouring coiling is in line with the current management routines. As 
endovascular coiling is the dominant treatment strategy since the introduction during 
the1990s (40) and represents 50-80% of current aSAH interventions (13).  
 
Despite the fact that aSAH management have improved during the last three decades e.g. 
imaging techniques, Nimodipine administration and coiling technics (18, 24, 27) 
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complications frequently occur after aSAH such as re-bleeding, acute hydrocephalus, CVS 
(typically day 3-14 post-ictus) and seizures (18, 41). More, at admission the most important 
factor related to outcome is the neurological condition, particularly the level of consciousness. 
Other prognostic factors are; age, location of the ruptured aneurysm and the amount of 
extravasated blood seen on CT scans (18, 44). Further, the recovery following aSAH vary 
considerably, as some patients obtain favourable recovery with mild sequelae, and other 
become totally dependent in every day life (2, 39). aSAH-survivors frequently receive both 
physical/neurological disabilities e.g. hemiparesis, dysphasia and hemianopia and 
psychological disabilities i.e. cognitive deficits and personality change, of these psychological 
disabilities have a major impact on functional outcome (2, 3, 6). However, recovery may 
occur over prolonged time (8), especially physical sequel, while psychological recovery is 
suggested to occur earlier, within 12 months (1). Although there are many opinions 
considering the endpoint of recovery following aSAH and consequently it needs to be further 
investigated (39, 45, 46).  
 
Admission	assessment		
Several rating scales exist at admission to assessing the initial clinical condition and the 
severity of SAH-patients e.g. Glasgow Coma Scale (GCS), Reaction Level Scale 85 (RLS85), 
World Federation of Neurological Surgeons scale (WFNS), Hunt and Hess scale (Hunt-Hess) 
and The Fischer scale (13, 47). Hunt-Hess, is a validated five-grading scale established on the 
level of consciousness, headache, neck stiffness and focal neurological deficits, often 
dichotomized in favourable (Hunt-Hess 1-3) and unfavourable (Hunt-Hess 4-5) grades (48). 
The scale is frequently used at admission, despite criticized for the subjective parameters and 
poor outcome discrimination (47, 49).  
 
Outcome	assessment	and	S-GOS	04	questionnaire			
There are several outcome measurements e.g. Glasgow Outcome Scale (GOS), GOSE, 
modified Rankin Scale (mRS, 0-6), National Institute of Health Stroke Scale (NIHSS, scale of 
focal neurological deficits) and Barthel Index (BI, 0-100, rating scale of activity of daily 
living, ADL) (13). We further address GOS and GOSE, especially the former as it was used 
to investigate long-term functional outcome of aSAH survivors (1, 2). Description of the five-
point GOS and eight-point GOSE are given in appendix, table A1. 
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GOS and GOSE are validated outcome measurements after traumatic brain injuries and non-
traumatic brain insults including aSAH. The scales are frequently applied worldwide and 
recommended to use in clinical trials (11, 46, 49-51). However, it is important to emphasize 
that GOS and GOSE scores indicate overall functional outcome including physical/ 
neurological deficits and psychological deficits (1, 2). In this master thesis we have used the 
term “functional” to describe overall functional outcome after aSAH. Further, GOS and 
GOSE focus on how the injury influence major area of life without receiving detailed 
information concerning the deficits and symptoms (51). Thus, the outcome measures only 
reflect the effect of the brain insult and not pre-existing injuries or chronic conditions (46).   
 
The five-point GOS is a hierarchical scale stratified into following five outcome categories: 1) 
death 2) persistent vegetative state 3) severe disability 4) moderate disability and 5) good 
recovery (1). Patients in a vegetative state are unconscious i.e. lack function in the cerebral 
cortex.  Severe disability represents patients, who are conscious, but dependent, i.e. need 
assistance in daily life. Patients assigned moderate disability are independent in daily life, but 
disabled i.e. posttraumatic signs are present. Good recovery implicates patients capable of 
resuming normal life even though minor neurological and psychological deficits exist (1, 2, 7, 
12, 46). However, to allow a more sensitive rating of conscious patients the eight-point 
extended GOS (GOSE) was developed (2, 51).  
 
The eight-point GOSE is identical to the five-point GOS expect for further outcome 
categories, as the upper three GOS categories (3-5) are subdivided into “better” and “worse” 
(2). Although, it has been reported that GOSE increase the inter-observer reliability with 
favourable agreement for GOS (92%) vs. (78%) (51, 52).  
 
Further, GOS and GOSE can be dichotomized in unfavourable outcome (GOS 1-3, GOSE 1-
4) i.e. death and independent status and favourable outcome (GOS 4-5, GOSE 5-8) i.e. 
independent status. This division is beneficial for statistical calculations, applied in this 
master thesis (2).  
 
To obtain practical and reliable outcome assessment after traumatic brain injuries and non-
traumatic brain insults guidelines and a standard well-specified questionnaire has been 
developed (51). Further, a Swedish version of GOS, S-GOS 04 has been established in 
accordance with Wilson et al. guidelines. The questionnaire protocol, S-GOS 04 was used in 
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this master thesis, shown in appendix. S-GOS 04 covers following areas: 1) independence at 
home 2) independence outside the home (shopping and traveling) 3) employability (work or 
study) 4) social and leisure activities and 5) interpersonal relationship (family and friendship). 
In addition there are equal questions concerning pre-injury status. Accordingly, this makes it 
possible to distinguish between disability caused by the brain insult from pre-existing injuries 
or chronic diseases (1, 12).  
 
Timing for outcome assessment frequently occurs at 3- or 6-months post-aSAH (3, 9, 53). 
Despite, Anderson et al. (46) have pointed out that later outcome evaluation at 12- and 24- 
months post-ictus is more reliable. Further, as already mention there are many opinions 
considering the endpoint of recovery and consequently the most appropriate time for outcome 
assessment is frequently discussed. Thus, so far no standardized time for outcome evaluation 
has been established (45, 46). Consequently, outcome after aSAH needs to be further 
investigated, especially a decade after the insult, as few studies exist. Thus, this prospectively 
cohort study 12-15 years post-aSAH may contribute to increased knowledge of functional 
recovery and mortality for this patient group.  
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AIM	 	
The primary aim of this master thesis was to investigate long-term morbidity and mortality 
after aSAH, utilizing GOS and relate these results to Kaplan-Meier survival curves. Further, 
we wanted to investigate the possibility to detect functional improvement with respect to 
previous GOS assessments at 1-year for the same patient cohort.  Although, we address 
aneurysm treatment strategies our objective was not to compare treatment paradigms. Finally, 
we analysed long-term overall mortality and did not investigate the actual death cause.  
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METHODS	
Ethics		
The present study was approved by the ethic committee at University of Gothenburg, 
approval number S 161-00 and complying to the Helsinki Declaration. Informed consent was 
obtained from patient or next-of kin at admittance to the SU after receiving both oral and 
written information. A supplement request for this long-term follow-up study was made and 
approved.  
 
Patients	
The present long-term cohort is established from prospectively collected data of consecutive 
aSAH-patients admitted to the NICU at SU, Gothenburg, Sweden between October 2000 and 
December 2003. The study design and characteristics of patients have previously been 
detailed described by Karin Nylén and Ludvig Zoltán Csajbók (12, 13). In this extended 
prospectively long-term follow-up study-patients were consecutively enrolled when fulfilling 
the inclusion criteria’s:   
• NICU admittance < 48 hours after the aSAH  
• Confirmed intracranial ruptured aneurysm by intra-arterial angiography, DSA, CTA or 
intra-operated detected 
•  Residing in Sweden for outcome assessment 
• Informed consent obtained from the patient or next-of-kin 
Further inclusion criteria was:  
• GOSE assessment at 1-year to explore change in long-term functional outcome. 
 
Thus patients were excluded when not fulfilling above inclusion criteria and if more than one 
aSAH was verified during the inclusion period, October 2000 to December 2003.  
 
Data	collection		
We reviewed the following prospectively collected data: date of aSAH onset i.e. day 0 the day 
of initial severe aSAH symptoms prior arrival to NICU at SU (12), admission date to NICU, 
gender, admission status evaluated with Hunt-Hess (1-5) and WFNS (1-5), outcome 
assessments including NIHSS and BI. WFNS, NIHSS and BI are not further evaluated in this 
study of the aSAH cohort of patients at 12-15 years post-ictus. Further, functional outcome at 
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1-year, according to the eight-point GOSE was assessed after the long-term outcome data was 
collected i.e. the current examiner was blinded to previous GOSE-results. Furthermore, we 
noted aneurysmal treatment strategy either by endovascular coiling, neurosurgical clipping, 
both interventions (coiling and clipping) or conservative treatment. Age at onset was 
calculated from birthdate to day 0 (approximated to whole year, cut-off at 6 months). Finally, 
data regarding the incidence of lifetime aSAH admitted to NICU at SU was collected through 
records (dead patients) or by telephone-interviews at 12-15 years follow-up (long-term 
survivors).  
 
Outcomes	
We prospectively investigated long-term functional outcomes and mortality with the five-
point GOS (1) and Kaplan-Meier survival curves.  
 
Functional	status	
GOS at 12-15 years post-aSAH, concerning long-term survivors were obtained by structured-
telephone interviews, according to the validated S-GOS 04 questionnaire protocol (shown in 
appendix), with the patient, next-of kin or the patient´s caretaker. The interviews were 
performed between: August 31, 2015 to October 10, 2015 after verifying that the patient was 
alive according to the Swedish death registry. Patients unavailable by phone were contacted 
through mail correspondence, then by a telephone interview. Further, one examiner, not 
involved in the acute care of the patients, blinded to GOSE-results at 1-year, performed all the 
interviews, applying guidelines i.e. used a standard written protocol followed by GOS 
assessment (51). In addition, the interviewer obtained instructions by Ingrid Eiving (present 
neurointensive nurse at SU, previously assessing functional outcome at 1-year). As described 
in the introduction, the eight-point GOSE is identical to five-point GOS, except for further 
outcome categories of conscious patients (2). Thus, we could calculate previous GOSE values 
(1-8) at 1-year to GOS scores (1-5) at 12-15 years post-ictus. Finally, the functional outcome 
scale was dichotomized in unfavourable (GOS 1-3) and unfavourable (GOS 4-5) outcomes, in 
agreement with previous investigations (12, 13).  
 
Long-term GOS change was calculated among survivors with assessed GOS scores at 1-year 
and at 12-15 years. Accordingly, we could analyse functional outcome over time. Change in 
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functional outcome was defined as a decrease or increase in at least one outcome category (1-
5) or change between unfavourable (GOS 1-3) and favourable (GOS 4-5) outcomes.   
 
Mortality	
The aim of this master thesis was to analyse long-term overall mortality/ survival i.e. the 
death from any cause. Thus, we did not investigate death cause and consequently did not 
obtain death certificates. However, deceased patients were identified until August 3, 2015 by 
search in the Swedish death registry and death date was noted. According to an inclusion 
period between October 2000 and December 2003, long-term aSAH survivors were assessed 
between 12 and 15 years post-aSAH. Survival probabilities were analysed for; 1) the entire 
study cohort, starting at aSAH onset and 2) subgroups stratified for age (younger <55years, 
older >55years), gender and treatment strategy (coiling vs. clipping). Further, we investigated 
survival probabilities for aSAH survivors at 1-year concerning GOS values (3-5) and 
dichotomized outcomes in unfavourable (GOS 2- 3) and favourable (GOS 4-5). Deaths in the 
study cohort were compared to (when appropriate) age, gender, calendar year and area (West 
Sweden) matched-controls from the Statistical Institute Sweden (SCB) (54).  
 
Statistical	methods		
Professional statistics assistance (Statistiska Konsultgruppen, Gothenburg, Sweden) was used 
to obtain the statistical analyses.  The statistical analyses were performed with SAS, System 
Version 9.4 (SAS Institute, Inc, Cary, NC, USA). Further, all significance tests were two-
sided and conducted at the 5% significance level. Sample size calculation to detect a 
difference have previous been performed and were therefore not repeated for this long-term 
follow-up study (41). The distribution of variables is given as mean, standard deviation (SD), 
median, minimum and maximum for continuous variables (age) and as number percentage for 
categorical variables (ordered and dichotomous). For comparison between two groups 
Mantel-Haenszel Chi Square Exact was used for ordered categorical variables (GOS 1-5 and 
Hunt-Hess 1-5), Mann-Whitney U-test for continuous variables and Fischer´s exact test for 
dichotomous variables (gender, age group, coil vs. op. and unfavourable vs. favourable 
outcome). Spermans´s rank correlation coefficient (rs) was used for all correlation analyses. 
Change over time in ordered categorical variables and dichotomous variables, was analysed 
with Sign test.  
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Kaplan-Meier survival curves were estimated to analyse overall survival and the end-point 
being time to death by any cause. The survival analyses were done until August 3, 2015. 
Patients alive after time to long-term follow-up were censored. We calculated Kaplan-Meier 
survival curves for the entire study cohort, stratified for age, gender and treatment starting at 
onset of the aSAH and at 1-year according to GOS values and dichotomized outcomes in 
unfavourable and favourable. We plotted simulated age, gender, calendar year and area-
matched normal population survival curves when appropriate. Log-rank test was used for 
comparison between survival curves. In order to calculate Hazard Ratio with 95% confidence 
interval (CI) a Cox proportional hazard regression model was performed.  
 
Standard mortality ratios (SMRs) were calculated to quantify the increase or decrease in 
mortality for the entire cohort and subgroups compared to age, gender, calendar year and 
area-matched controls. Observed person-year and observed deaths were calculated for the 
entire study-cohort from the time of the insult and according to outcome assessments, from 1-
year post-aSAH. The expected numbers of deaths were obtained by multiplication of number 
of observation years in each cell (based on age, gender, calendar year with probability of 
death in this cell in West of Sweden), data from SCB, summered up over all cells.  SMRs 
with exact 95% CI and p-values using Poisson-distribution from observed and expected 
number of deaths.  
 
In order to select predictors of long-term favourable outcome (GOS 4-5) univariable logistics 
regression analysis was applied to each predictor. Further, to select independent predictors of 
long-term favourable outcome significant predictors in the univariable analysis were entered 
into a multivariable stepwise logistic regression analysis. The results from the logistic 
regression analyses are given as Odds Ratio (OR) with 95% CI and p-values. The goodness of 
fit in the multivariable logistic regression is given as area under the receiver operator 
characteristic curve (AUCROC).   
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RESULTS		
Patients		
During the inclusion period (Oct 2000-Dec 2003) 212 consecutively patients admitted to 
NICU at SU were initial candidates to be study participants, of those 158 fulfilled the 
inclusions criteria’s. Accordingly, 54 patients were excluded: 4 patients admitted to NICU 
>48 hours, ruptured aneurysm was not proven in 40 patients (no aneurysm verified by intra-
arterial angiography, DSA or CTA in 32 cases and angiography was not performed in 8 
cases), informed consent was not obtained or was withdrawn in 8 cases, 1 patient was not 
residing in Sweden and 1 patient was initially included twice due to two aSAH insults during 
the inclusion´s period, therefore we excluded the second insult. Consequently, 158 patients 
remained and constitute the study population of this master thesis.  
 
Baseline characteristics of all aSAH patients and stratified for age (cut-off median age), 
gender, Hunt-Hess (1-5) and treatment strategy i.e. endovascular coiling vs. neurosurgical 
clipping are presented in table 1. Accordingly, the study population consisted of 114 women 
(72.2%) and 44 men (27.8%), mean age at onset of the haemorrhage was 55 years (SD 10.7) 
and median age 56 years (range 20-81 years). Further, we observed that men were significant 
younger (p=0.030) than women at onset of the haemorrhage. Mean age for men was 52.8 (SD 
9.9) and for women 56.2 (SD 10.9). Furthermore, there was a significant difference (p=0.036) 
between gender and Hunt-Hess with favourable grading i.e. less severe aSAH at admission 
for men. Endovascular coiling was the dominant aneurysmal intervention applied in 111 
patients (70.3%). Operation with neurosurgical clipping was performed in 40 cases (25.3%), 3 
patients (1.9%) underwent both coiling and clipping to occlude the aneurysm(s). Conservative 
treatment i.e. no active aneurysmal intervention was implemented in 4 cases (2.5%).  
 
Further, we identified six patients (3.8%) (3 men and 3 women), with two insults during their 
lifetime admitted to NICU at SU, of those 5 had multiple aneurysms and 2 patients are still 
living (2 women).  
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Table 1. Baseline characteristics of all aSAH-patients and stratified for age group and gender.  
  By age group By gender 
Variable 
Total Population 
(n=158) 
<55 years at onset 
(n=72) 
≥55 years at onset 
(n=86) p-value 
Male 
(n=44) 
Female 
(n=114) p-value 
Gender        
Male   44 (27.8%) 26 (36.1%) 18 (20.9%)  44 (100.0%)   
Female 114 (72.2%) 46 (63.9%) 68 (79.1%) 0.052  114 (100.0%)  
Age at onset 55.2 (10.7) 
56 (20; 81) 
n=158 
45.8 (6.7) 
47 (20; 54) 
n=72 
63.2 (5.9) 
62 (55; 81) 
n=86 
 52.8 (9.9) 
52 (34; 74) 
n=44 
56.2 (10.9) 
58.5 (20; 81) 
n=114 
0.030 
Treatment        
Coil 111 (70.3%) 48 (69.6%) 63 (76.8%)  32 (76.2%) 79 (72.5%)  
Op   40 (25.3%) 21 (30.4%) 19 (23.2%) 0.41 10 (23.8%) 30 (27.5%) 0.81 
Coil + Op 3 (1.9%)       
Conservative  4 (2.5%)       
Hunt and Hess        
1  29 (18.7%) 18 (26.1%) 11 (12.8%)  14 (31.8%) 15 (13.5%)  
2 47 (30.3%) 22 (31.9%) 25 (29.1%)  12 (27.3%) 35 (31.5%)  
3 44 (28.4%) 14 (20.3%) 30 (34.9%)  11 (25.0%) 33 (29.7%)  
4 25 (16.1%) 10 (14.5%) 15 (17.4%)  5 (11.4%) 20 (18.0%)  
5 10 (6.5%) 5 (7.2%) 5 (5.8%) 0.12 2 (4.5%) 8 (7.2%) 0.036 
For categorical variables n (%) is presented. For continuous variables Mean (SD) / Median (Min; Max) / n= is presented. 
For comparison between groups Fisher´s Exact test was used for dichotomous variables and the Mantel-Haenszel Chi Square Exact 
test was used for ordered categorical variables and the Mann-Whitney U-test was used for continues variables. Coil, endovascular 
coiling. Op, neurosurgical clipping. P-values, coiling vs. clipping is presented. Hunt-Hess, favourable 1-3, poor 4-5, missing, n=3. 
 
Outcomes	
Functional outcomes according to GOS at 1-year (n=150) and at 12-15 years (n=158) post-
aSAH, and mortality for the entire study cohort (n=158) until August 3, 2015 are shown in 
table 2. Thus, GOS results at 1-year were missing for 8 patients and no patient was in 
vegetative state (GOS 2) at any time.  
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Table 2. Functional outcomes by GOS scores and dichotomized in unfavourable and 
favourable outcomes at 1-year and at 12-15 years post-aSAH. Mortality from onset of the 
insult to the long-term follow-up is presented.  
 GOS Mortality  
Variable 
 1-year post-aSAH 
(n=150) 
12-15 years post- aSAH  
(n=158) 
Total deaths  
(n=55) 
GOS scores    
1 (dead) 23 (15.3%) 55 (34.8%)  
3 (severe disability) 26 (17.3%) 16 (10.1%)  
4 (moderate disability) 62 (41.3%) 24 (15.2%)  
5 (good recovery) 39 (26.0%) 63 (39.9%)  
Dichotomized outcomes     
Unfavourable (GOS 1-3) 49 (32.7%) 71 (44.9%)  
Favourable (GOS 4-5) 101 (67.3%) 87 (55.1%)  
Mortality      
Deaths within the first 30 days    15 (9.5%) 
Deaths between 30 days and 1-year   8 (5.1%) 
Deaths between 1-year and 12-15 years    32 (20.3%) 
Time to death (years)   4.84 (4.84) 
3.95 (0.01; 13.71) 
(n=55) 
For categorical variables n (%) is presented. For continuous variables Mean (SD) / Median (Min; Max) / n= is presented. 
GOS scores at 1-year, missing n=8. No one obtained GOS 2 (vegetative state) at any time.  
 
Functional	status		
GOS at 1-year; a major of the study cohort, 62 patients (41.3%) had moderate disability (GOS 
4) at 1-year follow-up. 26 patients (17.3%) assigned severe disability (GOS 3) i.e. were 
dependent in every day life. Favourable outcome (GOS 4-5) was identified in 101 patients 
(67.3%). Further, GOS at 1-year stratified for age (p=0.57), gender (p=0.30) and treatment 
strategy: coiling vs. clipping (p=0.76) did not show any significantly difference (shown in 
appendix, table A2).   
 
GOS was validated in all 103 survivors (65.2%) at 12-15 years post-aSAH i.e. complete long-
term follow-up. Outcome categories (GOS 3-5) were obtained by telephone-interviews from: 
patient (n=83), patient + next-of kin (n=1), patient + caretaker (n=1), only next-of kin (n=12), 
next of-kin + caretaker (n=3), and only caretaker (n=3). The majority of the study cohort, 63 
patients (39.9%) had good recovery (GOS 5) at 12-15 years post-aSAH. Moderate disability 
(GOS 4) was noted in 24 patients (15.2%). 16 patients (10.1%) had severe disability (GOS 3). 
Further, unfavourable outcome (GOS 1-3) was detected in 71 patients (45.9 %) and 
favourable outcome (GOS 4-5) was noted in 87 patients (55.1 %) at 12-15 post-ictus.  
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GOS assessments at long-term follow-up stratified for age, gender, treatment and admissions 
status (Hunt-Hess 1-5) are presented in table 3. There was no significant difference between 
gender and GOS values at 12-15 years post-aSAH (p=0.69). Further, a significant correlation 
regarding older age at onset and worse functional outcome was detected (p=0.024, rs -0.18). 
There was a significant difference between aneurysmal intervention and GOS scores 
(p=0.029), favouring clipping over coiling. Finally, poor Hunt-Hess (4-5) was significantly 
correlated with worse functional outcome at 12-15 years post-ictus (p=0.0008, rs-0.27).  
 
Table 3. GOS scores at 12-15 years post-aSAH stratified for age, gender, treatment and 
admission status.  
Variable 
1 
(n=55) 
3 
(n=16) 
4 
(n=24) 
5 
(n=63) p-value 
Gender      
Male   16 (29.1%) 7 (43.8%) 3 (12.5%) 18 (28.6%)  
Female 39 (70.9%) 9 (56.3%) 21 (87.5%) 45 (71.4%) 0.69 
Age at onset 59.2 (10.6) 
59.0 (32.0; 81.0) 
n=55 
52.5 (9.3) 
51.5 (34.0; 66.0) 
n=16 
50.6 (7.6) 
51.0 (39.0; 67.0) 
n=24 
54.2 (11.2) 
56.0 (20.0; 76.0) 
n=63 
0.024 
Coil/Op      
Coil 44 (88.0%) 9 (56.3%) 15 (62.5%) 43 (70.5%)  
Op   6 (12.0%) 7 (43.8%) 9 (37.5%) 18 (29.5%) 0.029 
Hunt and Hess      
1 6 (10.9%) 1 (6.7%) 5 (21.7%) 17 (27.4%)  
2 14 (25.5%) 5 (33.3%) 4 (17.4%) 24 (38.7%)  
3 18 (32.7%) 7 (46.7%) 8 (34.8%) 11 (17.7%)  
4 10 (18.2%) 2 (13.3%) 5 (21.7%) 8 (12.9%)  
5 7 (12.7%) 0 (0.0%) 1 (4.3%) 2 (3.2%) 0.0008 
For categorical variables n (%) is presented. For continuous variables Mean (SD) / Median (min; Max) / n = is presented. 
For comparison between groups the Mantel-Haenszel Chi Square Exact test was used for dichotomous variables and Spearman´s 
rank correlation test was used for continuous and ordered categorical variables. Coil, endovascular coiling. Op, neurosurgical 
clipping. Hunt-Hess, favourable 1-3, poor 4-5, missing n=3.   
 
GOS change from 1-year to 12-15 years post-aSAH, stratified for GOS scores (3-5) and 
dichotomized in unfavourable and favourable outcomes, only including survivors at 1-year 
(n=127) are summarized in table 4 and illustrated in figure 1. Whereas 23 patients died within 
1-year they are not considered regarding GOS change over long-time.  As mentioned earlier 
no patient estimated vegetative state (GOS 2) at any time i.e. change in functional outcome 
consider conscious patients at 1-year follow-up.  
 
Concerning GOS scores (3-5), 31 patients (24.4%) died between 1-year and 12-15 years post-
aSAH. A major patient population, 59 patients (46.5%) obtained equal outcome category at 1-
year and at 12-15 years. Further, 38 patients (29.9%) obtained a reduced outcome category. 
Approximately one forth (23.6%), 30 patients improved GOS scores over long-time. 
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Although changed in GOS categories were estimated between 1-year and 12-15 years post-
aSAH there was not a significant difference between decreased and increased GOS scores 
(p=0.40). Further, when dichotomizing patients into unfavourable (GOS 1-3) and favourable 
(4-5) outcome a significant decreases in outcome was noted  (p=0.0002). As result of that 22 
patients (17.3%) relocated from favourable to unfavourable outcome and 3 patients (2.4%) 
relocated from unfavourable to favourable outcome i.e. from dependency to independency.  
 
Table 4. GOS change from 1-year to 12-15 years post-aSAH, only including survivors at 1-
year follow-up (GOS 3-5).   
 
Change from 
1-year to 12-15 years follow-up 
Variable 
1-year follow 
up 
(n=127) 
12-15 years 
follow up 
(n=127) 
 
 p-value 
GOS scores  
     1            
     3            
     4            
     5            
 
0 (0.0%) 
26 (20.5%) 
62 (48.8%) 
39 (30.7%) 
 
31 (24.4%) 
14 (11.0%) 
21 (16.5%) 
61 (48.0%) 
Decrease 38 (29.9%) 
Equal 59 (46.5%) 
Increase 30 (23.6%) 0.40 
Dichotomized outcomes 
     Unfavourable (GOS 1-3) 
     Favourable (GOS 4-5) 
 
26 (20.5%) 
101 (79.5%) 
 
45 (35.4%) 
82 (64.6%) 
Decrease 22 (17.3%) 
Equal 102 (80.3%) 
Increase 3 (2.4%) 0.0002 
For categorical variables n (%) is presented. For comparison over-time, Sign test was used for 
categorical variables. GOS scores: 1=dead, 3=severe disability, 4=moderate disability, 5=good recovery.  
 
Detailed description of changes in functional outcomes within each GOS category among the 
127 survivors at 1-year to 12-15 years are depicted in figure 1. Concerning the 26 patients 
having severe disability (GOS 3) at 1-year, the majority, 16 patients (62%) died, 7 patients 
(27%) remained at the same outcome level, and 3 patients (12%) improved to good recovery 
(GOS 5) i.e. relocated from dependency to independency. Further, of those 62 patients 
assigned moderate disability (GOS 4) at 1-year a minority, 14 patients (22%) decreased 
outcome scores: 7 patients died and 7 patients trans located to severe disability (GOS 3). 21 
patients  (34%) had equal functional outcome level and the majority, 27 patients (44%) 
improved to good recovery (GOS 5). Finally, of those 39 patients having good recovery (GOS 
5) at 1-year, an excessive majority, 31 patients (79%) remained at the same functional level 
over long-time. Approximately one fifth, 8 patients (21%) died. 
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Figure 1. GOS change among the 127 aSAH survivors at 1-year to 12-15 years and deaths 
within 1-year. Staples represent GOS at 1-year and colours GOS at 12-15 years. GOS 1=dead, 
GOS 3=severe disability, GOS 4=moderate disability and GOS 5=good recovery.  
 
In addition, we analysed GOS change between 1-year and 12-15 years stratified for age and 
gender (shown in appendix, table A3 and A4). Age dichotomized in two groups, cut-off 
median age: younger (<55 years, n=64) and older (≥55 years, n=71) patients did not 
significant influence change in GOS, neither in GOS scores (p=0.73) nor dichotomized 
outcomes in unfavourable and favourable (p=0.45). Further, there was no significant 
difference between gender and change in GOS scores or dichotomized outcomes (adjusted p 
for age and Hunt-Hess: p=0.057 and p= 0,47 respectively).  
 
Mortality		
The distribution of death rates within long-term follow-up (until August 3, 2015) is listed in 
table 2. Accordingly, of all 158 aSAH-patients enrolled in this study, 55 patients (34.8%) died 
during the long-term follow-up period, median 3.95 years (range 0.01-13.7 years) post-ictus. 
Thus, we identified 15 deaths (9.5%) within the first 30 days, 8 patients (5.1%) died between 
30 days and 1-year and 32 patients (20.3%) died between 1-year and time for long-term 
follow-up (last death occurred July 30, 2015). Consequently, 103 aSAH survivors (65.2%) 
were identified. The survival time was mean 13.3 years (range 11.6-14.8 years) post-aSAH, 
depending on when the patient was included between October 2000 and December 2003. 
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Kaplan-Meier survival curves of all aSAH patients (n = 158) and stratified for GOS, age, 
gender and treatment strategy are presented in figures 2-6. SMRs are shown in appendix, table 
A4 and A5.  In the Kaplan-Meier survival curves censured observations i.e. long-term 
survivors (n=103) are visualized with vertical lines. The cumulative survival probability is 
represented on the y-axel and numbers at risk indicated on the x-axel at six time points.  
 
Figure 2. Illustrates survival curves of all aSAH patients (n=158) from onset of the insult to 
long-term follow-up compared to age, gender, calendar year and area-matched controls. There 
was a statistically significant increased mortality for aSAH-patients; SMR 3.50 (95 % CI 2.6– 
4.6, p<0.0001) compared matched controls.  
 
Figure 2. Kaplan-Meier survival curves of all aSAH-patients (n=158) compared to matched 
controls. 95 % CI is plotted and censured observations i.e. long-term survivors (n=103) 
indicated with vertical lines.  
 
Figure.3 illustrates long-term survival probability of all aSAH-patients still alive at 1-year (n 
= 127) dichotomized in unfavourable (GOS 3) and favourable (GOS 4-5) outcomes compared 
to age, gender, calendar year and area-matched controls, respectively. Thus, survivors at 1-
year dichotomized into unfavourable outcome (n = 26) had statistically significant increased 
mortality compared to the matched controls, SMR 4.27 (95 % CI 2.4-6.9, p < 0.0001). This 
increased mortality was not observed in patients with favourable outcome (n = 101) at 1-year, 
SMR 1.4 (95 % CI 0.78 – 2.3, p = 0.27). Further, there was a significant difference between 
patients with favourable and unfavourable outcomes (log rank p<0.0001) Hazard Ratio = 0.16 
(0.08; 0.32). 
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In addition, we investigated the correlation between GOS score (3-5) at 1-year and long-term 
survival probability. There was a significant correlation between worse GOS value at 1-year 
and increased mortality (log rank p=0.0003). As mention above and depicted in figure 3 
patients assigned GOS 3 (unfavourable outcome, n=26) had significantly increased mortality 
than matched controls SMR 4.27 (95% CI 2.44-6.93 p<0.0001). This evaluated mortality was 
not significant for patients with GOS 4 and 5, SMR 1.38 (95% CI 0.56-2.85, p=0.49) and 
SMR 1.39 (95% CI 0.60-2.73, p=0.45), respectively.
 
Figure 3. Kaplan-Meier survival curves divided in unfavourable (GOS 3) and favourable 
(GOS 4-5) outcomes at 1-year compared to respective matched controls.  
 
Survival curves stratified for two age groups are depicted in figure 4. There was a significant 
difference between younger (<55 years) and older (≥55 years) aSAH-patients (log rank 
p=0.012). Further, both younger and older patients had significantly increased mortality 
compared to matched controls, SMR 7.09 (95 % CI 4.13 – 11.35, p<0.0001 and SMR 2.86 
(95 % CI 2.02 – 3.92, p<0.0001), respectively.  
 
Comparison of survival curves according to gender did not show significant difference (log 
rank p=0.75), shown in figure 5. Further, both men (n=44) and women (n=114) had 
approximately 3.5 times higher mortality than matched controls. The increased mortality was 
significant both for men SMR 3.45 (95% CI 1.97-5.60, p<0.0001) and women SMR 3.53 
(95% CI 2.51-4.82, p<0.0001).   
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Survival curves in patients who underwent endovascular coiling (n=111) and neurosurgical 
clipping (n=40) are presented in figure 6. There was a significant different survival 
probability between the interventions (log rank p=0.0089), favouring surgical treatment. 
Further, patient treated with coiling had a significant increased mortality than matched 
controls SMR 3.69 (95% CI 2.68-4.95 p<0.0001). The evaluated mortality was not significant 
for an operative treatment strategy, SMR 1.67 (95% CI 0.61-3.63, p=0.31).  
 
 
Figure 4. Survival curves according to 
two age groups: <55 vs. ≥55 years.  
 
Figure 5. Survival curves according to 
gender. 
Figure 6. Survival curves according to 
treatment: coiling vs. clipping.  
 
 
Prediction	of	long-term	favourable	outcome		
The results concerning predictors of long-term favourable outcome (GOS 4-5) from onset of 
the aSAH are shown in appendix, table A7. Hence, univariable significant predictors of 
favourable outcome at 12-15 years post-ictus were low age; OR per ten year 0.66, p=0.0095 
and low Hunt-Hess; OR per ten year 0.66, p=0.0057. In the multivariate model both, age 
adjusted OR 0.68 and Hunt-Hess adjusted OR 0.68 were included, AUCROC: 0.67 (95% CI 
0.58-0.76).  
 
Predictors of long-term favourable outcome at 1-year follow-up are presented in appendix, 
table A8. Thus, univariable significant predictors of favourable outcome at 12-15 years post-
aSAH were low age; OR per ten year 0.62, p=0.012, high GOS at 1-year; OR 4.88, p<0.0001 
and favourable outcome at 1-year; OR 27.5, p<0.0001. In the multivariate model both age 
adjusted OR 0.57, and GOS at 1-year adjusted OR 5.02 were included, AUCROC: 0.79 (95% 
CI 0.71-0.88). Further, no predictive values were shown for gender (univariabale p=0.25 and 
0.17) and treatment strategy (univaraible p=0.098 and 0.41) at neither time-point.  
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DISCUSSION	
In this prospectively study cohort, conducted on 158 aSAH-patients admitted to NICU at SU 
between October 2000 and December 2003 outcome was investigated 12-15 years post-ictus. 
We focused on long-term morbidity and mortality, validated by GOS. We found that 
individual functional improvement occurred between 1-year and 12-15 years after the 
haemorrhage. Although at cohort level deterioration was noted. Further, we detected that 
GOS assessment at 1-year was a useful predictor of long-term mortality and functional 
outcome. Thus, patients with favourable outcome (i.e. independency) at 1-year follow-up had 
the same long-term life expectancy as the general population, while patients with 
unfavourable outcome (i.e. dependency) had >4 times increased mortality than similar 
matched controls. More, the best indicators of long-term favourable prognosis were high GOS 
scores and low age at 1-year follow-up. Finally, high age and severe clinical status, but not 
gender, were risk factors for poor outcome.  
 
Initially, we discovered that our patient-cohort had similar characteristic’s concerning; age 
(55.2 years), gender (72.2% female), clinical admission status (77.4% Hunt-Hess 1-3) vs. 
others (7-9, 18, 24, 27, 49, 55). When scrutinizing our material we observed that male patients 
were younger (52.8 years) than female (56.2 years), in accordance with previous studies (4, 
24, 56). Further, we detected that female patients were admitted in worse clinical condition 
(higher Hunt-Hess) than male patients. These results comply with Koffijberg et al. (27) 
reported higher case fatality rate within the first 28 days in women (32.5%) than in men 
(30.5%). Conclusively, women seem to be older and in a more severe condition than men at 
University Hospital admission. The dominant aneurysmal treatment of the patients was 
endovascular coiling (70.3%), in agreement with the therapy trend during the 2000s, 
favouring coiling over clipping (13, 24). Further, approximately one third (32.7%) was 
assigned unfavourable outcome at 1-year i.e. dead or dependency, as reported in larger studies 
(49, 57). In conclusion, our study cohort of 158 aSAH patients has similar characteristics as 
other studies, indicating that our results may be generally applicable.  
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Hypotheses	
Hypothesis	1	–	functional	improvement			
Our first hypothesis was that it possible to detect functional improvement >1-year post-aSAH. 
Our results demonstrated that long-term functional recovery is possible in conscious patients 
at 1-year, either by increased GOS scores and/ or change from unfavourable to favourable 
outcome i.e. from dependency to independency. A forth (23.6%) of the 127 survivors at 1-
year increased their functional recovery, primarily from moderate disability to good recovery. 
Further, in the 26 patients with unfavourable outcome i.e. severe disability at 1-year, 
approximately 12% improved and relocated to good recovery. In addition, we detected that 1-
year survivors with good recovery, either stayed at the same functional level or died similarly 
as matched healthy controls. Conclusively, our findings show that recovery following aSAH 
is a long-term dynamic process as deterioration and improvement occurred between 1-year 
and 12-15 years post-ictus and the incidence of recovery was greatest of those with moderate 
disability at 1-year. Hence, the endpoint of functional outcome is beyond 1-year post-aSAH.  
 
The possibility of long-term recovery is in agreement with other studies (8, 9). Thus, Wilson 
et al. (9) investigated clinical improvement within a period of 3-years, by mRS in poor-grade 
aSAH patients (Hunt-Hess 4-5). They observed that 19% of the 75 available patients 
improved at least one mRS grade between 1- and 3-years post-ictus. However, few studies 
have investigated long-term clinical outcomes beyond 10-years. The only previous study 
found was Grebbe et al. (8) analysing functional outcomes by mRS and quality of life (QoL) 
with the short form 36 (SF-36) and visual analogue scale (VAS) at 5-years and 12.5-years 
post-aSAH and compared the results with previous follow-up investigations at 4- and 18-
months. The authors found functional improvement between 4-months and 5-years in 55.5% 
(29 of 52 patients), but no further recovery to 12.5-years, although increased QoL. This 
prospective study has some limitations. Firstly, it is a relative small cohort, as only 52 patients 
was available at the 5-years follow-up and secondly, 5 patients were lost to long-term follow-
up. Contrary, the probability to detect functional recovery is higher in our prospective long-
term follow-up study, among the 127 survivors at 1-year. As all 103 patients still living at 12-
15 years post-ictus were structured interviewed according to GOS. Thus, we identified 
individual long-term functional recovery in 30 patients (23.6%) and of those 3 patients (2.3%) 
relocated from severe disability to good recovery from 1-year to 12-15 years after the aSAH.  
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We observed that recovery following aSAH is a long-term dynamic process, in accord with 
other investigations (7, 9). Whereas similar proportion deteriorated and improved GOS scores 
over time; 29.9% and 23.6%, significant decrease in outcome was only detected when 
dichotomizing outcome into unfavourable and favourable. In agreement with Svensson et al. 
(7) we identified highest recovery potential in those who were found to have moderate 
disability at 1-year.  
 
When scrutinizing age and gender we identified that younger (<55years) and older (≥55years) 
conscious patients at 1-year recovered similarly over long-time. This observation is in line 
with Wilson et al. (9) who reported that aSAH patients <65years had higher potential for 
improvement beyond 6 months, although not beyond 1-year, than those >65years of age. 
When investigating gender, our results demonstrated that men and women have comparable 
probability for functional improvement beyond 1-year, in accord with Wilson et al. (9). 
However, the influence of age and gender of long-term functional recovery need to be 
investigated further in larger patient cohorts.   
 
To conclude, we found that long-term functional improvement is possible at the individual 
level, both in independent and dependent patients at 1-year. One forth improved GOS scores 
and in those having severe disability, 12% relocated to favourable outcome between 1-year 
and 12-15 years post-ictus. Patients with moderate disability at 1-year have the highest 
potential to further recovery. Although at cohort level deterioration was detected when 
dichotomizing patients into unfavourable and favourable outcome. Conclusively, our results 
demonstrate that outcome assessment may be appropriate beyond 1-year, as long-term 
recovery is possible. Thus giving the patient, their families and caregivers important 
knowledge.  
 
Hypothesis	2	–	mortality		
Our second hypothesis was that patients with aSAH have increased long-term mortality 
compared matched controls. We found this hypothesis to be true as aSAH-patients had 3.5 
times higher long-term mortality compared to the control population. Further, the mortality in 
aSAH-patients 12-15 years post-ictus was 35%. However, surprisingly, our results 
demonstrated that survivors at 1-year with favourable outcome i.e. independency had similar 
survival probability as age-, gender-, calendar year- area-matched controls, while patients 
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with unfavourable outcome i.e. dependency had 4.3 times excess mortality than the control 
population. Conclusively, the long-term mortality is increased in patients with aSAH vs. 
matched controls. However, the novel finding in this study is that patients with favourable 
functional outcome at 1-year follow-up had the same long-term life expectancy as the general 
population.  
 
The long-term mortality of 35% is in line with other studies (10, 49, 55, 58, 59). Contrary to 
our results, Wermer et al. (59) prospectively study, found that independent patients at 1-year 
had reduced survival probability compared to a matched control population. The study by 
Wermer and co-workers, though larger (n=752) has several limitations. Their patients were 
only surgical treated and they had an earlier inclusion-period; 1985 to 2001 when new 
treatments i.e. endovascular coiling was introduced during the 1990s (24, 40). Thus, our 
results with an inclusion-period between 2000 and 2003 and with the majority (70%) being 
coiled may be more generally applicable.  
 
We investigated long-term mortality including confounding factors like age, gender and 
treatment strategy at onset of the aSAH. We found that younger (<55 years), independent of 
gender, had favourable survival probability than older (≥55 years) patients. This is not 
surprising and in agreement with several studies (10, 18, 24, 27, 47, 49, 60). The striking 
enhanced mortality for younger (<55years) patients, approximately 7 times, may be explained 
by the fact that younger healthy individuals have lower yearly mortality. Further, as already 
mention, gender did not influence long-term mortality, previous demonstrated (10, 24). 
Interestingly, our results suggest beneficial long-term survival probability for neurosurgical 
clipping over endovascular coiling, opposed to larger multicentre, randomized studies (e.g. 
ISAT and Barrow Ruptured Aneurysm Trial, BRAT) (43, 61). However, these results must be 
interpreted with caution, as aneurysms in the posterior circulation is difficult and hazardous to 
secure and is if possible/ often endovascular treatment of choice (18). Further, patients in this 
study were not randomized to treatment paradigms.  
 
Finally, it is relevant to know whether long-term morbidity and mortality have improved with 
the established treatment routines at SU over the past. This includes CT angiography, 
Nimodipine administration, improved intensive care and endovascular coiling techniques. The 
appreciations of these new procedures/ treatments have reduced both morbidity and mortality 
during the past three decades (11, 24). For instance Naval et al. (11) observed that functional 
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outcomes after aSAH estimated 30-120 days post-discharge by dichotomized GOS in 
favourable (GOS 4-5) have improved in the decade of 2001 to 2009 (71.5%) compared to 
1991 to 2001 (65.2%). In accord with these result Nieuwkamp et al. (24) stated in a meta-
analysis that case-fatality rates have decreased with 17% between 1973 and 2000. In addition, 
a Swedish retrospective study in >18000 aSAH-patients between1987 to 2002 reported that 
both the incidence and case-fatality rates have decreased over time (27). Conclusively, as the 
treatment routines (according to the standardized protocol) at SU are similar since early 2000s 
we can conclude that the management of aSAH-patients in our study cohort probably has 
contributed to beneficial outcomes compared to previous treatment paradigm.  
 
In summary, life expectancy is reduced in aSAH survivors independent of gender. Further, 
our results demonstrate that independent patients i.e. dichotomized in favourable outcome at 
1-year have similar survival probability compared to age-, gender-, calendar year-, area-
matched controls. Therefore, we speculate that patients with unfavourable outcome at 1-year 
should have periodical intermittent follow-ups as individual recovery is possible to occur over 
long-time. Finally, the financial applications of our research may be great.  
 
Hypothesis	3	–	outcome	prediction		
To facilitate management decision and as a consequent of that current admission scales (GCS, 
RLS 85, Hunt-Hess, WFNS, Fischer scale) are claimed to poorly predict outcome (13, 47) we 
investigated predictors of long-term favourable outcome i.e. independency. We found 
independent significant predictors of long-term favourable outcome at onset of the 
haemorrhage; low age, low Hunt-Hess grade and at 1-year; low age, high GOS scores and 
favourable outcome. The best indicators of long-term favourable prognosis were GOS and 
age at 1-year follow-up.  
 
As mentioned, the prognostic accuracy was greatest for GOS at 1-year combined with age, as 
AUCROC in the multivariate model was 0.79 (95% CI 0.71-0.88). In addition, GOS scores and 
dichotomized outcome in favourable (i.e. independency) were separately moderate/ strong 
significant predictors of long-term favourable outcome, as AUCROC was similar (0.74, 
p<0.0001). Interestingly, Rosen et al. (49) in a large multicentre study among 3567 aSAH 
patients compared their created grading scale with the WFNS. They demonstrated favourable 
prognostic accuracy for their scale (AUCROC 0.78 vs. 0.74, p<0.05). Hence, the prognostic 
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accuracy that we demonstrated for GOS at 1-year together with age is greater and maybe 
useful to add in clinical practice to facilitate clinical decisions.  
 
Further, low age and low Hunt-Hess grade were significant independent predictors (separately 
and together) of long-term favourable outcome, although the prognostic value was poor. 
AUCROC in the multivariate model including age and Hunt-Hess at admission was 0.67 (95% 
CI 0.58-0.76). Concerning age, the prognostic value were poor both at admission and at 1-
year (AUCROC 0.62, p=0.019 and p=0.016). The negative association with increasing age at 
admission and outcome has previously been demonstrated (27, 47, 49, 60), though the 
prognostic value beyond 1-year is questioned in agreement with our findings. For instance 
Wilson et al. (9) observed that age <65years was not associated with clinical improvement 
after 1-year. Further, Hunt-Hess predictive value should be interpreted with caution, even if it 
has been associated with outcome (9, 47, 49). Firstly our results indicate poor prognostic 
value and secondly the admission scale has been criticized for high inter-observer variability 
and poor outcome discrimination (47, 49). Accordingly, age and Hunt-Hess predictive value 
of long-term favourable outcome need to be further investigated.  
 
Furthermore, no predictive values were shown for gender, previously reported (9, 49) and 
treatment strategy (coiling vs. clipping) at admission or at 1-year, in accord with (9).  
 
In conclusion, among the variables found to be independent predictors of favourable outcome 
at 12-15 years after the insult, GOS scores and favourable outcome at 1-year were the 
strongest predictors and the best indicators of long-term favourable prognosis were GOS and 
age at 1-year follow-up. As described in the introduction, GOS is a current useful tool 
worldwide in outcome assessment, despite most frequently used within the first 6 months (1, 
3, 9, 13, 53). Our findings suggest that GOS is a valuable outcome tool at 1-year and 
consequently may an appropriate complement in clinical practice.  
 
Methodological	considerations	
Strengths		
The major strength of this single centre prospectively cohort study was the complete long-
term follow-up, 12-15 years after the aSAH. All the 103 survivors were structured-telephone 
interviewed, according to validated GOS and mortality was demonstrated for the entire study 
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cohort. Further, all interviews were performed by the same (trained) examiner, blinded to 
previous GOSE results at 1-year and had not been involved in the acute care of the patient in 
agreement with current guidelines (51). In addition, the standardized questionnaire protocol 
(S-GOS 04) made the results valuable i.e. received high inter- and intra-observer agreement 
(46). Further, in accordance with the detailed follow-up at 1-year (performed by the same 
neurologist), we could compare functional outcome between 1- and 12-15 years post-aSAH. 
Another strength was that we could evaluate management routines of this particular patient 
cohort, as our patient cohort is from the same geographical area (West Sweden), have 
received management at NICU at SU according to an established protocol. Finally, we 
adjusted for age, gender, calendar year and geographical area (West Sweden) and used 
matched controls in all our analyses.  
 
Limitations	
Limitations consider GOS assessment should be acknowledged. Firstly, it is subjective 
outcome assessment and therefore combined with inter- and intra-observer variability (46, 62, 
63). However, this is an issue of all rating scales. As mention above we tried to prevent 
uncertainty, by adopting guidelines for the interviews (51), and applied a validated standard 
questionnaire (S-GOS 04). Further, GOS has been criticized to be insensitive and 
emphasizing physical rather than cognitive and emotional deficits (45, 46, 52). Hence, we 
may have oversight the actual improvement beyond 1-year and neglected psychological 
deficits that have a major impact on functional outcome (1). Further, pre-existing 
injuries/diseases and naturally aging have might confounding GOS rating. Further, I would 
suggest adaption of the S-GOS 04 to a more appropriate questionnaire for long-term outcome 
estimation, as the question concerning employability was inconsistent in this aging 
population. Finally, outcome assessment based on direct patient contact (as the 1-year follow-
up) would have been desirable (46). Although hard to achieve, for instance appointment 
attendance may contribute to high incidence of dropouts.   
 
Other limitations need to be considered. We have probably underestimated the accurate 
mortality, as the most severe patients, outside downtown Gothenburg, do not reach the 
University Hospital (12, 13). Our results demonstrated 9.5% deaths within the first 30 days, in 
contrary to Koffjiberg et al. (27) retrospectively study in Sweden reporting 31.7% case-
fatality rate within the first 28 days. Although, mortality rates based on retrospectively 
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collected data are associated with uncertainty. In addition, case-fatality rates vary 
considerable between medical centres in the world (10% to 60%) (24, 39). Further, selection 
bias may have skewed our results comparing the interventions; coiling vs. clipping. As 
already mention, coiling have been restricted to poor surgical candidates e.g. patients with 
greater medical comorbidities and increased age that may prevent generalising our findings 
(13). Finally, we did not adjust for modifiable risk factors for aSAH such as smoking, 
hypertension and excessive alcohol intake (30, 34). However, we adjusted for age, gender, 
calendar year and area.  
 
Further	studies		
In future, when performing extensive long-term follow-ups after aSAH, it would be desirable 
with more frequent time-points for outcome estimation, to specify when improvement occurs. 
Further, neuropsychiatric testing should be a consideration, especially of those in the upper 
functional outcome categories (GOS 4-5). Concerning our study cohort, I would suggest 
continual follow-ups of young (<55 years) aSAH-patients to analyse the mortality compared 
to matched controls. In addition, it would be interesting to continue to follow the 
unfavourable (GOS 3) study cohort to investigate if long-term recovery is possible to occur 
beyond 15-years. Further, for comparison of long-term outcome between medical centres in 
Sweden and according to the high incidence of aSAH in the north (27), an extended follow-up 
in this geographical area would be valuable. Finally, we have investigated the overall long-
term mortality i.e. the actual death causes remain to be examined. In addition the correlation 
with modifiable risk factors such as hypertension, smoking and excessive alcohol 
consumption (30, 34) and long-term outcome persist to be further investigated.  
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CONCLUSIONS	
• Functional improvement was possible at the individual level between 1 and 12-15 
years post-aSAH. Both concerning increased GOS scores and relocation from 
dependent (GOS 3) to independent (GOS 4-5) status. The majority of long-term 
recovery appeared in patients with moderate disability at 1-year and in patients with 
good recovery, a majority (79%) stayed at the same functional outcome level over 
long-time.   
• Patients with aSAH had independent of gender 3.5 times increased mortality as the 
general population. Although, patients with favourable outcome at 1-year had the 
same long-term life expectancy compared to matched controls, while dependent 
patients had 4.3 times excess mortality.  
• GOS was a validated tool at 1-year to predict long-term favourable outcome at 12-15 
years post-aSAH. The best indicators of long-term favourable prognosis were GOS 
and age at 1-year follow-up.  
• High age and low Hunt-Hess grade, but not gender, were risk factors of long-term 
poor outcome.  
 
Medical	relevance	
Our findings indicate that GOS at 1-year may be a valuable tool in clinical practice to predict 
long-term prognosis, both concerning mortality and functional status. As patients with 
favourable outcome at 1-year had the same long-term life expectancy as the general 
population and of those, younger patients had the greatest possibility to an independent status 
12-15 years post-aSAH. While patients with severe disability at 1-year had enhanced 
mortality, but at individual level recovery is possible over time. Thus, a better functional 
status may be possible to obtain with rehabilitation. Conclusively, GOS long-term predictive 
value may be a complement to facilitate clinical decision-making and enable comparison of 
outcome between medical centres.  
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POPULÄRVETENSKAPLIG	SAMMANFATTNING	
Subarachnoidalblödning (SAH) är en undergrupp av stroke som oftast (85 %) beror på ett 
brustet pulsåderbråck s.k. aneurysm lokaliserat på skallbotten som medför att blod sprids 
utanför hjärnan. Denna hjärnblödning har vi studerat. Det mest karakteristiska symtomet för 
insjuknandet i en aneurysmal subarachnoidalblödning (aSAH) är plötslig, intensiv huvudvärk. 
Övriga kännetecken för aSAH är att den företrädvis drabbar medelålders kvinnor, är vanligare 
i norra än i södra Sverige, samt är associerad med hög sjuklighet och dödlighet. 
Komplikationer uppkommer ofta, varav den mest fruktade är en efterföljande blödning. 
Därför är det viktigt att omedelbart sluta det brustna aneurysmet på en neurokirurgisk klinik. 
Oftast (50-80%) sker det med röntgenledd teknik då aneurysmet packas med platinaspiraler 
s.k. coils via inträde från ett blodkärl i ljumsken. Det andra alternativet är en omfattande 
operation som involverar ingrepp via skallbenet och hjärnan för att sluta aneurysmet med en 
metall-klämma s.k. clip. Därefter krävs fortsatt intensivvård och rehabilitering.  
 
Trots den dåliga prognosen är återhämtning efter aSAH möjlig över tid. Dagens forskning är 
däremot inte överens om över hur lång tid förbättringen kan fortgå. Dessutom är följderna 
mer än tio år efter hjärnblödningen bristfälligt studerat. Därför initierade vi denna studie, 12-
15 år efter insjuknandet i aSAH baserat på en studiegrupp från Västra Götalandsregionen som 
insjuknat mellan 2000-2003 och behandlas på Sahlgrenska Universitetssjukhuset.  
 
För att studera det långsiktiga utfallet efter aSAH telefonintervjuade vi alla levande patienter 
baserat på ett validerat och strukturerat frågeformulär, Glasgow Outcome Scale (GOS). 
Därmed kunde vi gradera patienternas funktionsstatus (1-5). Avlidna efter hjärnblödningen 
identifierades genom sökning i dödsregistret. Slutligen analyserades data av statistiska 
experter.  
 
Vi fann att individuell förbättring var möjlig mer än ett år efter aSAH, men på gruppnivå 
skedde framförallt en försämring. Vi upptäckte att patienter med bra funktionsstatus vid ett år 
efter hjärnblödningen hade samma förväntade överlevnad som övriga befolkning, medan svårt 
funktionsnedsatta patienter hade en påtaglig ökad dödlighet. Vidare fann via att den 
långsiktiga prognosen påverkades av åldern, men inte kön.  
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Våra upptäckter kan vara användbara för vårdpersonal för att få en vägledning om 
patienternas långsiktiga prognos. Där de med en ettårsuppföljning, innefattande gradering av 
funktionsstatus enligt GOS kan få en indikation om vilka patienter som behöver ökad 
rehabilitering och tätare uppföljning för att förhoppningsvis förbättras. Därmed gynnas 
patienter, anhöriga och samhället.  
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APPENDICES	
Assessment	tool:	GOS	and	S-GOS	04	questionnaire	
Table A1. GOS and GOSE description.  
 GOS GOSE Definition 
P 
O 
O 
R 
1 1 Death 
2 2 Vegetative state 
3 3 Lower severe disability 
3 4 Upper severe disability 
G 
O 
O 
D 
4 5 Lower moderate disability 
4 6 Upper moderate disability 
5 7 Lower good recovery 
5 8 Upper good recovery 
Dichotomized outcomes in unfavourable (GOS 1-3, GOSE 1-4) and favourable (GOS 4-5, GOSE 5-8). 
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S-GOS 04-questionnaire, pages 1 and 2 
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Stratified	GOS	at	1-year,	table	A2	
Table A2. GOS scores at 1-year post-aSAH stratified for age, gender and treatment.  
Variable 
1 
(n=23) 
3 
(n=26) 
4 
(n=62) 
5 
(n=39) p-value 
Gender      
Male   6 (26.1%) 9 (34.6%) 10 (16.1%) 16 (41.0%)  
Female 17 (73.9%) 17 (65.4%) 52 (83.9%) 23 (59.0%) 0.57 
Age at onset 57.0 (11.7) 
57.0 (32.0; 75.0) 
n=23 
58.8 (10.1) 
59.0 (34.0; 79.0) 
n=26 
53.8 (8.2) 
54.5 (38.0; 68.0) 
n=62 
55.4 (13.9) 
58.0 (20.0; 81.0) 
n=39 
0.30 
Coil/Op      
Coil 17 (94.4%) 16 (61.5%) 40 (64.5%) 33 (89.2%)  
Op   1 (5.6%) 10 (38.5%) 22 (35.5%) 4 (10.8%) 0.76 
For categorical variables n (%) is presented. For continuous variables Mean (SD) / Median (min; Max) / n = is presented. 
For comparison between groups the Mantel Haenszel Chi Square Exactest was used for ordered categorical variables.  
GOS at 1-year n=150. Coil, endovascular coiling. Op, neurosurgical clipping.  
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Stratified	GOS	change	over	long-time,	table	A3-4	
Table A3. GOS at 1-year and at 12-15 years and change in GOS by age group: <55yeras vs. ≥55 years, only including survivors at 1-year.    
 
<55 Years at onset 
(n=64) 
≥55 Years at onset 
(n=71)  
Variable n (%) 
p-value 
within 
group n (%) 
p-value 
within 
group 
p-value 
between 
groups 
GOS scores at 1-year      
3 8 (14.3%)  18 (25.4%)   
4 31 (55.4%)  31 (43.7%)   
5 17 (30.4%)  22 (31.0%)  0.45 
GOS scores at 12-15 years      
1 9 (14.1%)  23 (32.4%)   
3 9 (14.1%)  7 (9.9%)   
4 16 (25.0%)  8 (11.3%)   
5 30 (46.9%)  33 (46.5%)  0.069 
Change in GOS scores: 1 to 12-15 years      
Decrease 11 (19.6%)  27 (38.0%)   
Equal    32 (57.1%)  27 (38.0%)   
Increase 13 (23.2%) 0.84 17 (23.9%) 0.17 0.18 
Change in Outcomes: 1 to 12-15 years      
Decrease 7 (12.5%)  15 (21.1%)   
Equal    49 (87.5%)  53 (74.6%)   
Increase 0 (0.0%) 0.016 3 (4.2%) 0.0075 0.67 
For categorical variables n (%) is presented. For comparison between groups the Mantel-Haenszel Chi Square Exact test was 
used for ordered categorical variables. For comparison within groups Sign test was used. GOS 1=dead, GOS 3=severe 
disability, GOS 4=moderate disability and GOS 5=good recovery. GOS at 1-year consider survivors, n=127, missing n=8. 
Change in GOS scores and dichotomized outcomes: unfavourable (GOS 3) vs. favourable (GOS 4-5) are presented. 
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Table A4. GOS at 1-year and at 12-15 years and change in GOS by gender, only including 
survivors at 1-year.   
 
Male 
(n=38) 
Female 
(n=97)  
Variable n (%) 
p-value 
within 
group n (%) 
p-value 
within 
group 
p-value 
between 
groups 
Adjusted 
p-value* 
GOS scores at 1-year       
3 9 (25.7%)  17 (18.5%)    
4 10 (28.6%)  52 (56.5%)    
5 16 (45.7%)  23 (25.0%)  0.40 0.90 
GOS scores at 12-15 years       
1 10 (26.3%)  22 (22.7%)    
3 7 (18.4%)  9 (9.3%)    
4 3 (7.9%)  21 (21.6%)    
5 18 (47.4%)  45 (46.4%)  0.55 0.18 
Change in GOS scores: 1 to 12-15 years       
Decrease 12 (34.3%)  26 (28.3%)    
Equal    18 (51.4%)  41 (44.6%)    
Increase 5 (14.3%)  0.14 25 (27.2%) 1.00 0.22 0.057 
Change in Outcomes: 1 to 12-15 years       
Decrease 8 (22.9%)  14 (15.2%)    
Equal    26 (74.3%)  76 (82.6%)    
Increase 1 (2.9%) 0.039 2 (2.2%) 0.0042 0.48 0.47 
For categorical variables n (%) is presented. For comparison between groups the Mantel-Haenszel Chi Square Exact test was used for 
ordered categorical variables. For comparison within groups Sign test was used. 
*) Adjusting for age at onset and Hunt-Hess using Logistic regression. 
GOS 1=dead, GOS 3=severe disability, GOS 4=moderate disability and GOS 5=good recovery. GOS at 1-year consider survivors, 
n=127, missing n=8. Change in GOS scores and dichotomized outcomes: unfavourable (GOS 3) vs. favourable (GOS 4-5) are 
presented. 
 
 
Standard	mortality	ratios,	table	A5-6	
Table A5. SMRs for the entire study cohort at onset of the aSAH according to age group, 
gender, admission status and treatment compared to age, gender, calendar year and area 
matched-controls.  
Label 
Number of 
observations 
Observed 
person 
years 
Observed 
deaths 
Expected 
deaths 
SMR 
value 95% CI p-value 
All aSAH patients  158 1633.4 55 15.70 3.50 2.64 - 4.56 <.0001 
Age <55 years at onset 72 802.6 17 2.40 7.09 4.13 - 11.35 <.0001 
Age ≥55 years at onset 86 830.9 38 13.30 2.86 2.02 - 3.92 <.0001 
Male 44 442.6 16 4.64 3.45 1.97 - 5.60 <.0001 
Female 114 1190.8 39 11.06 3.53 2.51 - 4.82 <.0001 
Hunt and Hess 1 29 348.0 6 2.44 2.46 0.90 - 5.35 0.076 
Hunt and Hess 2 47 528.3 14 7.14 1.96 1.07 - 3.29 0.030 
Hunt and Hess 3 44 438.9 18 3.99 4.51 2.67 - 7.13 <.0001 
Hunt and Hess 4 25 228.0 10 1.81 5.53 2.65 - 10.18 <.0001 
Hunt and Hess 5 10 54.8 7 0.25 27.57 11.09 - 56.81 <.0001 
Coil 111 1123.9 44 11.94 3.69 2.68 - 4.95 <.0001 
Op 40 480.3 6 3.60 1.67 0.61 - 3.63 0.31 
Op, neurosurgical clipping. Hunt-Hess favourable 1-3, poor 4-5, missing, n=3. 
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Table A6. SMRs according to unfavourable and favourable outcomes and GOS scores (3-5) at 
1-year post-aSAH compared to age, gender, calendar year and area matched-controls.  
Label 
Number of 
observations 
Observed 
person 
years 
Observed 
deaths 
Expected 
deaths 
SMR 
value 95% CI p-value 
Favourable outcome (GOS 4-5) 101 1180.2 15 10.82 1.39 0.78 - 2.29 0.27 
Unfavourable outcome (GOS 3) 26 227.8 16 3.75 4.27 2.44 - 6.93 <.0001 
GOS 3 (severe disability) 26 227.8 16 3.75 4.27 2.44 - 6.93 <.0001 
GOS 4 (moderate disability) 62 738.2 7 5.06 1.38 0.56 - 2.85 0.49 
GOS 5 (good recovery) 39 442.0 8 5.77 1.39 0.60 - 2.73 0.45 
 
 
Predictors	of	long-term	favourable	outcome,	table	A7-8	
Table A7. Prediction of long-term favourable outcome at onset of the aSAH.  
 Univariable* Multivariable** 
Variable n missing Value 
n (%) of 
event 
OR (95%CI) 
Unfavourable 
favourable 
outcome at 12-
15 years after 
aSAH p-value 
Area under 
ROC-Curve 
(95%CI) 
OR (95%CI) 
Unfavourable 
favourable 
outcome at 12-
15 years after 
aSAH p-value 
Gender 0 Male 21 (47.7%)      
  Female 66 (57.9%) 1.51 (0.75-3.03) 0.2508 0.54 (0.47-
0.61) 
  
Age at onset (OR per 10 years) 0 20-<51 34 (65.4%)      
  51-<61 34 (59.6%)      
  61-81 19 (38.8%) 0.66 (0.48-0.90) 0.0095 0.62 (0.53-
0.71) 
0.68 (0.49-0.94) 0.0194 
Coil/ Op 7 Coil 58 (52.3%)      
  Op 27 (67.5%) 1.90 (0.89-4.05) 0.0982 0.56 (0.49-
0.63) 
  
Hunt and Hess 3 1 22 (75.9%)      
  2 28 (59.6%)      
  3 19 (43.2%)      
  4 13 (52.0%)      
  5 3 (30.0%) 0.66 (0.50-0.89) 0.0057 0.63 (0.54-
0.71) 
0.68 (0.51-0.91) 0.0103 
P-values, OR and Area under ROC-curve are based on original values and not on stratified groups. OR is the ratio for an increase of the 
predictor of one unit. 
*) All tests are performed with univariable logistic regression. 
**) Multivariable logistic regression model including age at onset and Hunt and Hess grade. 
Area under ROC-curve with 95% CI for multivariable model = 0.67 (0.58-0.76). 
Coil, endovascular coiling. Op, neurosurgical clipping. Hunt-Hess, favourable 1-3 and poor 4-5.   
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Table A8. Prediction of long-term favourable outcome at 1-year post-aSAH.  
 Univariable* Multivariable** 
Variable n missing Value 
n (%) of 
event 
OR (95%CI) 
Unfavourable 
favourable 
outcome at 12-
15 years after 
aSAH p-value 
Area under 
ROC-Curve 
(95%CI) 
OR (95%CI) 
Unfavourable 
favourable 
outcome at 12-
15 years after 
aSAH p-value 
Gender 0 Male 21 (55.3%)      
  Female 66 (68.0%) 1.72 (0.80-3.72) 0.1652 0.56 (0.47-
0.64) 
  
Age at onset (OR per 10 years) 0 20-<51 34 (73.9%)      
  51-<60 27 (64.3%)      
  60-81 26 (55.3%) 0.62 (0.43-0.90) 0.0118 0.62 (0.52-
0.72) 
0.57 (0.36-0.90) 0.0155 
Coil/Op 2 Coil 58 (61.7%)      
  Op 27 (69.2%) 1.40 (0.63-3.10) 0.4115 0.53 (0.45-
0.61) 
  
GOS scores at 1-year  8 3 3 (11.5%)      
  4 48 (77.4%)      
  5 31 (79.5%) 4.88 (2.50-9.52) <0.0001 0.74 (0.65-
0.84) 
5.02 (2.52-9.99) <0.0001 
Unfavourable/favourable outcome 
at 1-year  
8 Unfavourable 
Outcome 
3 (11.5%)      
  Favourable 
Outcome 
79 (78.2%) 27.52 (7.56-
100.21) 
<0.0001 0.74 (0.66-
0.81) 
  
P-values, OR and Area under ROC-curve are based on original values and not on stratified groups. OR is the ratio for an increase of the 
predictor of one unit. 
*) All tests are performed with univariable logistic regression. 
**) Multivariable logistic regression model including age at onset and GOS at 1-year. 
Area under ROC-curve with 95% CI for multivariable model = 0.79 (0.71-0.88). 
Coil, endovascular coiling. Op, neurosurgical clipping. GOS 3=severe disability, GOS 4=moderate disability and GOS 5=good recovery. 
Dichotomized outcomes in unfavourable (GOS 3) and favourable (GOS 4-5). 
 
 
 
 
 
